Clinical trial
Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for…
NCT00198237 · Indiana University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00198237 |
|---|---|
| Title | Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer |
| Official title | Genomic and Proteomic Analysis of Docetaxel and Capecitabine as Primary Chemotherapy for Stage II-III Breast Cancer |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel & capecitabine |
| Enrollment | 40 |
| Start date | Mar 1, 2003 |
| Completion | Dec 1, 2005 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 3, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: